An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2

Gene Therapy

Volumn 4, Issue 4, 1997, Pages 317-322

  Wright, M ^a   Grim, J ^a   Deshane, J ^a   Kim, M ^a   Strong, T V ^a   Siegal, G P ^b   Curiel, D T ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Breast cancer; ErbB 2; Gene therapy; Single chain antibody

Indexed keywords

ANTIBODY; ONCOPROTEIN;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENDOPLASMIC RETICULUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; VIRUS RECOMBINANT;

EID: 0030935529     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300372     Document Type: Article

References (26)

1. Coussens L et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132-1139.
2. Yamamoto T et al. Similarity of protein encoded by the human c-erbB-2 gene to the epidermal growth factor receptor. Nature 1986; 319: 230-234.
3. Slamon DJ et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
4. Weiner DB et al. Expression of the neu gene-encoded protein (p185neu) in human non-small cell carcinomas of the lung. Cancer Res 1990; 50: 421-425.
5. Fukushige S et al. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 1986; 6: 955-958.
6. Semba K, Kamata N, Toyoshima K, Yamamoto T. A v-erbB-related proto-oncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 1985; 82: 6497-6501.
7. Kraus MH, Popescu NC, Amsbaugh SC, King CR. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 1987; 6: 605-610.
8. Hynes NE, Gerber HA, Saurer S, Groner B. Overexpression of the c-erbB-2 protein in human breast rumor lines. J Cell Biochem 1989; 39: 167-173.
9. Iglehart JD et al. Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 1990; 50: 6701-6707.
10. Hollywood DP, Hurst HC. A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. EMBO J 1993; 12: 2369-2375.
11. Slamon DJ et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
12. Borg A et al. Her-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990; 50: 4332-4337.
13. Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30 year follow-up. J Clin Oncol 1992; 10: 1044-1048.
14. Deshane J et al. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Therapy 1994; 1: 332-337.
15. Beerli RR, Wels W, Hynes NE. Intracellular expression of single chain antibodies reverts erbB-2 transformation. J Biol Chem 1994; 269: 23931-23936.
16. Deshane J et al. Intracellular antibody directed against erbB-2 mediates tumor cell eradication by inducing apoptosis. Cancer Gene Ther 1996; 3: 89-98.
17. Deshane J et al. Targeted tumor killing via an intracellular antibody against erbB-2. J Clin Invest 1995; 96: 2980-2989.
18. Deshane J et al. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gynecol Oncol 1995; 59: 8-14.
19. Kallioniemi OP et al. ErbB-2 amplification in breast cancer analyzed by flourescence in situ hybridization. Proc Natl Acad Sci USA 1992; 89: 5321-5325.
20. Dawkins HJ et al. C-erbB-2 amplification and overexpression in breast cancer: evaluation and comparison of Southern blot, slot blot, ELISA and immunohistochemistry. Pathology 1993; 25: 124-132.
21. Her-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res 1995; 55: 5400-5407.
22. Clinical Protocols. Cancer Gene Ther 1995; 2: 137-145.
23. Disis ML et al In vitro generation of human cytolytic T cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res 1994; 54: 1071-1076.
24. Moritz D, Winfried W, Mattern J, Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for erbB2-expressing tumor cells. Proc Natl Acad Sci USA 1994; 91: 4318-4322.
25. Fendly BM et al The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer. J Biol Resp Mod 1990; 9: 449-455.
26. Grim J et al. ErbB-2 knockout employing an intracellular singlechain antibody (sFv) accomplishes specific cytotoxicity in erbB-2 expressing lung cancer cells. Am J Resp Cell Mol Biol 1996, 15: 348-354.